Loading...
XNAS
RIGL
Market cap873mUSD
Dec 05, Last price  
48.92USD
1D
3.25%
1Q
18.34%
Jan 2017
105.55%
IPO
-92.30%
Name

Rigel Pharmaceuticals Inc

Chart & Performance

D1W1MN
XNAS:RIGL chart
P/E
49.93
P/S
4.87
EPS
0.98
Div Yield, %
—
Shrs. gr., 5y
-36.21%
Rev. gr., 5y
24.77%
Revenues
179m
+53.38%
16,526,00033,473,00012,600,0000750,000125,000,0004,750,0002,250,0007,150,0008,250,00028,895,00020,383,0004,484,00044,509,00059,288,000108,621,000149,236,000120,242,000116,882,000179,278,000
Net income
17m
P
-45,256,000-37,637,000-74,272,000-132,346,000-111,547,00037,890,000-85,973,000-98,840,000-89,027,000-90,908,000-51,464,000-69,216,000-77,992,000-70,480,000-66,546,000-30,391,000-17,914,000-61,596,000-25,091,00017,485,000
CFO
31m
P
-35,170,000-35,836,000-52,207,000-103,518,000-102,779,00046,743,000-69,375,000-85,192,000-86,061,000-69,753,000-23,413,000-75,889,000-77,557,000-58,826,000-41,510,000-52,185,0005,878,000-73,758,000-5,743,00031,471,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Rigel Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs to treat hematologic disorders, cancer, and rare immune diseases. The company offers Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia. It also develops Fostamatinib that is in phase III clinical trial for the treatment of warm autoimmune hemolytic anemia; phase III clinical trial for the treatment of hospitalized COVID-19 patients; and phase III clinical trial for the treatment of COVID-19. In addition, the company is developing R289, an oral interleukin receptor associated kinase 1/4 inhibitor, which is in phase I clinical trial for autoimmune, inflammatory, and hematology-oncology diseases; and R552, a receptor-interacting serine/threonine-protein kinase 1 inhibitor that has completed phase I clinical trial for autoimmune and inflammatory diseases. It has research and license agreements with AstraZeneca AB for the development and commercialization of R256, an inhaled JAK inhibitor; BerGenBio AS for the development and commercialization of AXL inhibitors in oncology; and Daiichi Sankyo to develop murine double minute 2 inhibitors for solid and hematological malignancies, as well as license and supply agreement with Kissei Pharmaceutical Co., Ltd. to develop and commercialize Fostamatinib. The company also has a license agreement and strategic collaboration with Eli Lilly and Company to co-develop and commercialize R552 for various indications, including autoimmune and inflammatory diseases, as well as other non-central nervous system (non-CNS) disease development candidates. Rigel Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in South San Francisco, California.
URL
https://www.rigel.com/
IPO date
Nov 29, 2000
Employees
155
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT